Skip to main content
LIFECORE BIOMEDICAL, INC. \DE\ logo

LIFECORE BIOMEDICAL, INC. \DE\ — Investor Relations & Filings

Ticker · LFCR ISIN · US5147661046 LEI · 549300EHBZ5OM9ND9O43 US Manufacturing
Open in API
Filings indexed 1,096 across all filing types
Latest filing 2012-01-05 Interim / Quarterly Rep…
Country US United States of America
Listing US LFCR

About LIFECORE BIOMEDICAL, INC. \DE\

https://www.lifecore.com/

Lifecore Biomedical is an integrated contract development and manufacturing organization (CDMO) that specializes in sterile injectable pharmaceutical drug products and medical devices. The company provides a full range of services, including specialty formulation, process development, aseptic filling, and final packaging, supporting products from clinical phases through to commercial supply. A key area of expertise is the handling of complex and highly viscous formulations. In addition to its CDMO capabilities, Lifecore is a primary producer of non-animal-sourced sodium hyaluronate (hyaluronic acid), offering it in various molecular weights and formats, including bulk material, hydrogels, and filled syringes and vials for diverse applications.

Recent filings

Filing Released Lang Actions
FORM 10Q
Interim / Quarterly Report Q2 2012
2012-01-05 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 3, 2012, reporting the issuance of a press release announcing consolidated financial results for the second quarter and first half of fiscal year 2012. The document explicitly states that the press release is attached as Exhibit 99.1 and is incorporated by reference. The text clarifies that the information is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, indicating this is a current report announcing financial results rather than the full financial report itself. The document length is 3176 characters, which is relatively short and consistent with an announcement rather than a full report. The content corresponds to an initial announcement of quarterly/periodical financial results, which fits the definition of an Earnings Release (ER). Therefore, the appropriate classification is ER with high confidence.
2012-01-03 English
PRIMARY DOCUMENT
Director's Dealing
2011-12-27 English
10B-5
Director's Dealing
2011-10-31 English
PURCHASE
Director's Dealing
2011-10-24 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated October 13, 2011, reporting several corporate governance events: retirement of a board member, resignation and election of directors, amendment of bylaws, and detailed voting results from the Annual Meeting of Stockholders. The key content includes the departure and election of directors and the submission of matters to a vote of security holders with detailed voting results. The presence of Item 5.02 (Departure of Directors or Certain Officers) and Item 5.07 (Submission of Matters to a Vote of Security Holders) strongly indicates this is a Board/Management Information filing and Declaration of Voting Results respectively. However, since the document includes both management changes and detailed voting results, the primary focus is on the management changes and board composition updates. The document is not a full annual report, audit report, or earnings release. It is not a proxy solicitation or presentation. The detailed voting results are part of the 8-K but the main emphasis is on management and board changes. Therefore, the best classification is Board/Management Information (MANG).
2011-10-18 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.